Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR444245 (THOR-707) + pembrolizumab/cetuximab in advanced gastrointestinal cancers
NCT05104567Phase 2Completed
- Sponsor
- Sanofi
- Start
- Dec 2021
- Primary completion
- Jul 2023
- Modality
- Cytokines & Interferons
- Countries
- 9
01
Overview
A Phase 2 trial of pegenzileukin in Esophageal Squamous Cell Carcinoma (ESCC), gastric cancer (GC), gastroesophageal junction adenocarcinoma, hepatocellular carcinoma (HCC), colorectal cancer (CRC), sponsored by Sanofi. Started Dec 2021; status: completed.
02
Drugs
pegenzileukin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)gastric cancer (GC)gastroesophageal junction adenocarcinomahepatocellular carcinoma (HCC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05104567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05104567.